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The IRF8-dependent subset of classical dendritic
cells (cDCs), termed cDC1, is important for cross-
priming cytotoxic T cell responses against patho-
gens and tumors. Culture of hematopoietic progeni-
tors with DC growth factor FLT3 ligand (FLT3L) yields
very few cDC1s (in humans) or only immature ‘‘cDC1-
like’’ cells (in the mouse). We report that OP9 stromal
cells expressing the Notch ligand Delta-like 1 (OP9-
DL1) optimize FLT3L-driven development of cDC1s
from murine immortalized progenitors and primary
bone marrow cells. Co-culture with OP9-DL1
induced IRF8-dependent cDC1s with a phenotype
(CD103+ Dec205+ CD8a+) and expression profile
resembling primary splenic cDC1s. OP9-DL1-
induced cDC1s showed preferential migration to-
ward CCR7 ligands in vitro and superior T cell
cross-priming and antitumor vaccination in vivo.
Co-culture with OP9-DL1 also greatly increased the
yield of IRF8-dependent CD141+ cDC1s from human
bone marrow progenitors cultured with FLT3L. Thus,
Notch signaling optimizes cDC generation in vitro
and yields authentic cDC1s for functional studies
and translational applications.INTRODUCTION
Dendritic cells (DCs) link innate and adaptive immunity by recog-
nizing pathogens through pattern recognition receptors such as
Toll-like receptors (TLRs) and recruiting diverse immune cells to
orchestrate antigen (Ag)-specific adaptive responses (Pulen-
dran, 2015; Steinman, 2012). Classical or conventional DCs
(cDCs) are specialized Ag-presenting cells with a characteristic3658 Cell Reports 23, 3658–3672, June 19, 2018 ª 2018 The Authors
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(MHC) class II expression, and a unique capacity for priming
naive T cells. Upon Ag capture, cDCs upregulate chemotactic re-
ceptors such as CCR7, migrate from tissues into the T cell areas
of regional lymphoid organs, secrete cytokines and chemokines,
and present Ag to Ag-specific T cells. As such, cDCs hold great
promise as cellular vaccines for eliciting Ag-specific immune re-
sponses, in particular to tumor antigens (Palucka and Bancher-
eau, 2013).
In the mouse, cDCs are comprised of two main subsets:
CD8+/CD103+ cDCs capable of Ag cross-presentation to
CD8+ T cells and CD11b+ cDCs specialized in the presentation
of exogenous Ag to CD4+ T cells (Merad et al., 2013; Mildner
and Jung, 2014; Schraml and Reis e Sousa, 2015). Both subsets
are conserved in humans (Haniffa et al., 2015) and have recently
been designated as cDC1 and cDC2, respectively (Guilliams
et al., 2014). All DCs, including cDCs and the related lineage
of interferon-producing plasmacytoid DCs (pDCs), develop in
the bone marrow (BM) in a process driven mainly by the cyto-
kine FLT3 ligand (FLT3L). Progenitors committed to cDC sub-
sets (pre-DCs) exit the BM and undergo terminal differentiation
in peripheral lymphoid organs and tissues. The development of
DC subsets is driven by several transcription factors, such as
IRF8, which is absolutely required for cDC1 differentiation in
mice (Aliberti et al., 2003; Sichien et al., 2016) and in humans
(Bigley et al., 2017; Hambleton et al., 2011). Additional factors,
such as BATF3 and other BATF family members, cooperate
with IRF8 to facilitate optimal development of cDC1s (Hildner
et al., 2008; Murphy et al., 2016). In addition to these cell-
intrinsic factors, terminal cDC differentiation in the periphery is
guided by tissue-specific signals, such as lymphotoxin-b and
Notch.
Notch is an evolutionarily conserved pathway of cell-cell
communication that informs cells of their surroundings and,
thereby, guides their differentiation. Vertebrate Notch receptors
(NOTCH1–4) transmit signals from membrane-bound ligands
of the Delta-like (DL) and Jagged (Jag) families through the.
commons.org/licenses/by/4.0/).
common transcription factor CSL (also called RBPJ). Notch
signaling plays an essential role in the development of immune
cell types that differentiate in distinct anatomical niches. For
instance, DL4-NOTCH1 and DL1-NOTCH2 signaling is required
for the specification of T cells in the thymus and of marginal
zone (MZ) B cells in the spleen, respectively (Radtke et al.,
2013). Indeed, co-culture of stem/progenitor cells with a murine
stromal cell line OP9 expressing DL1 (OP9-DL1) has become a
standard approach to generate T cells in vitro (Schmitt et al.,
2004; Mohtashami et al., 2016). Using DC-specific gene target-
ing, we have established the role of NOTCH2 receptor signaling
in the differentiation of a cDC2 subset in the spleen and intes-
tine (Caton et al., 2007; Lewis et al., 2011). In particular, splenic
cDC2 contains a lymphotoxin-b- and NOTCH2-RBPJ-depen-
dent Esamhi subset that is required for optimal CD4+ T cell
priming. These studies also revealed the reduction of Notch2-
deficient splenic CD8a+ cDC1s (Lewis et al., 2011), which
was subsequently ascribed to their impaired differentiation
and aberrant phenotype (Satpathy et al., 2013). Finally, DL1 ex-
pressed on fibroblasts has been identified as the relevant
ligand of NOTCH2 on splenic cDCs (Fasnacht et al., 2014).
Thus, NOTCH2 signaling mediated by DL ligands on stromal
cells controls the phenotypic and functional differentiation of
both cDC subsets.
Because primary DCs (particularly cDC1s) are rare in vivo, their
study and translational applications require methods to generate
functional DC subsets in vitro. Commonly used cultures of pri-
mary BMwith the cytokine granulocyte-monocyte colony-stimu-
lating factor (GM-CSF) produce a mixture of cDC2-like cells and
macrophages (Helft et al., 2015) but no cDC1s. Cultures of mu-
rine BM supplemented with the physiological cytokine FLT3L
produce a mixture of pDCs, cDC2s and cDC1-like cells (Naik
et al., 2005). The latter express appropriate transcription factors,
including IRF8, but have an abnormal phenotype, including a
lack of key cDC1 markers (e.g., CD8a, CD103, and Dec205)
and aberrant expression of cDC2 markers (e.g., CD11b). Human
hematopoietic stem and progenitor cells cultured with FLT3L
and other cytokines and/or stromal cells can produce CD141+
cDC1s with the expected expression profile and in vitro func-
tional properties (Balan et al., 2014; Lee et al., 2015; Poulin
et al., 2010; Proietto et al., 2012). However, the yield of cDC1s
has been very low in all reported protocols. Thus, new ap-
proaches are necessary to produce the full spectrum and high
numbers of fully differentiated DCs, particularly of functional
cDC1s.
Given the important role of Notch signaling in cDC differentia-
tion in vivo, we hypothesized that it would facilitate cDC differen-
tiation in vitro. We now report that combination of FLT3L-driven
differentiation of murine hematopoietic progenitors with the well-
established OP9-DL1 system produces optimally differentiated
cDC subsets, including bona fideCD8a+ Dec205+ cDC1. The re-
sulting cDC1s showed improved migration properties and
superior T cell cross-priming capacity in vivo. Furthermore, co-
culture of human hematopoietic progenitors with OP9-DL1
enhanced the generation of functional human cDC1s. These re-
sults emphasize the key role of Notch signaling in terminal cDC
differentiation and facilitate the generation of functional cDC1s
for translational applications.RESULTS
Notch Signaling Enables cDC1 Differentiation of
Immortalized DC Progenitors
To optimize DC production in vitro, we initially studied the differ-
entiation of DC progenitors that were conditionally immortalized
with the estrogen-dependent HoxB8 oncogene (Redecke et al.,
2013). In this system, progenitors can be grown indefinitely in the
presence of FLT3L and estrogen, whereas estrogen withdrawal
induces spontaneous FLT3L-driven DC differentiation within
7 days. Although HoxB8-FL (FLT3L) cells were originally re-
ported to produce all DC subsets, we never observed the pro-
duction of CD24+ or CD8a+ cDC1s from the original HoxB8-FL
line or from any newly derived lines (Figure 1A). To mimic Notch
signals received by committed cDC progenitors in vivo, we
differentiated HoxB8-FL cells for 3 days to initiate DC develop-
ment and then plated them on a monolayer of OP9-DL1 cells
or control GFP-transduced OP9 cells for the last 4 days of cul-
ture. Control OP9 cells inhibited the development of B220+
pDCs and yielded only CD11bhi CD24 CD8a cDC2s in lower
numbers (Figure 1A and data not shown). Co-culture with OP9-
DL1 largely abolished pDC development and reduced the yield
of cDC2s; however, it induced the generation of a distinct cDC
subset with theCD11bCD24+CD8a+ phenotype of cDC1s (Fig-
ures 1A and 1B).
To confirm that the observed DL1-driven cDC1 generation is
NOTCH2-dependent, we used an antibody (Ab) that blocks the
activation of NOTCH2 (anti-N2) (Wu et al., 2010). The administra-
tion of this anti-N2 Ab in vivo recapitulated the effects of DC-spe-
cific NOTCH2 blockade, including ablation of splenic Esamhi
cDC2s and of intestinal CD11b+ CD103+ cDCs and loss of
CD8a+ splenic cDC1s (Figure S1 and data not shown). The addi-
tion of anti-N2 to HoxB8-FL co-cultures with OP9-DL1 did not
rescue pDC loss (Figure 1C), further suggesting that this loss is
caused by OP9 cells independent of DL1 expression. On the
other hand, anti-N2 reduced the development of cDC2s and
largely abolished the development of cDC1s (Figure 1C). To
test the function of NOTCH2 ligands, we used OP9 cells trans-
duced with DL4 (OP9-DL4), which are as efficient as OP9-DL1
in driving T cell development (Mohtashami et al., 2016).We found
that OP9-DL4 were able to induce cDC1 differentiation of
HoxB8-FL cells, but less efficiently than OP9-DL1 (Figure 1D).
Collectively, these data show that DL1-NOTCH2 signaling can
elicit de novo generation of cDC1s from immortalized DC
progenitors.
Notch Signaling InducesOptimal cDC1Differentiation of
BM Progenitors
Having established the OP9-DL1 co-culture system of DC differ-
entiation, we applied it to the cultures of primary BM. Total BM
cells were either cultured for 7 days using a standard DC differ-
entiation protocol in FLT3L-containing medium or transferred
on day 3 to monolayers of OP9-DL1 in the continued presence
of FLT3L (hereafter referred to as FL or FL-Notch cultures,
respectively). As described previously (Naik et al., 2005), DCs
generated in FL cultures (DCFL) comprised B220+ pDCs,
CD11b+ CD24 cDC2s, and CD11b+/low CD24+ cDC1-like cells
(Figure 2A). Co-culture with control OP9 cells impaired theCell Reports 23, 3658–3672, June 19, 2018 3659
Figure 1. DL1-NOTCH2 Signaling Induces Differenti-
ation of cDC1s from a DC Progenitor Cell Line
The HoxB8-FL cell line was induced to differentiate in vitro by
estrogen withdrawal in the presence of FLT3L alone (FL),
FLT3L with control OP9 cells (FL+OP9), or FLT3L with OP9
cells expressing the Notch ligand DL1 (FL+Notch). OP9 cells
were added on day 3, and HoxB8-FL cells were analyzed on
day 7 of differentiation.
(A) Representative staining plots of differentiated HoxB8-FL
cells. The top row shows total live cells with B220+ MHC
class IIlo pDCs and B220 MHC class IIhi cDCs highlighted;
the other rows show gated cDCs with CD11bhi cDC2s and
CD11blo/ cDC1s highlighted.
(B) The subset composition of differentiated HoxB8-FL cells.
Shown are fractions of pDCs (of total live cells) and cDC
subsets (of gated cDCs) and the absolute number of these
subsets per 105 initial undifferentiated cells. Data represent
mean ± SD of 6 parallel cultures, representative of 3 experi-
ments.
(C) The effect of NOTCH2 blockade on HoxB8-FL cell dif-
ferentiation. HoxB8-FL cells were differentiated in FL+Notch
cultures in the presence of anti-NOTCH2 blocking Ab
(anti-N2) at 50 ng/ml (gray open bars) or 500 ng/ml (gray
textured bars); the fractions of DC subsets are shown as
above. Data represent mean ± SD of 5 parallel cultures.
(D) The effect of Notch ligands on HoxB8-FL cell differenti-
ation. HoxB8-FL cells were differentiated in co-cultures with
OP9 cells expressing the Notch ligand DL1 or DL4; the
fractions of DC subsets are shown as above. Data represent
mean ± SD of 6 parallel cultures.
Statistical significance: ****p < 0.0001; ***p < 0.001;
**p < 0.01; ns, not significant.
3660 Cell Reports 23, 3658–3672, June 19, 2018
AC
D E
F
G
H
B
(legend on next page)
Cell Reports 23, 3658–3672, June 19, 2018 3661
generation of pDCs and cDC1-like cells, yielding primarily cDC2s
(Figures 2A–2C). In contrast, co-culture with OP9-DL1 inhibited
pDC but not cDC development; moreover, the resulting DC
population (DCFL-Notch) contained two fully resolved subsets,
including a distinct CD11b CD24+ cDC1 population that ex-
pressed Dec205 and CD8a (Figures 2A–2C). In contrast to
cDC1-like cells from FL cultures (cDC1FL), CD24+ cDC1s from
FL-Notch cultures (cDC1FL-Notch) downregulated CD11b, ac-
quired expression of Dec205 and CD8a, and upregulated
CD103 (Figure 2D). Staining for additional subset markers re-
vealed a similarly improved resolution of the two cDC subsets
in FL-Notch cultures (Figure S2A). In particular, cDC2FL ex-
pressed low levels of the cDC1 markers Xcr1 and Clec9a, which
were reduced in cDC2FL-Notch; conversely, cDC1FL-Notch ex-
pressed Xcr1 and Clec9a but lacked the cDC2 markers CD11b
and CD172a/Sirpa (Figure S2A). All DCFL-Notch had higher levels
of CD11c and reduced levels of surface MHC class II; the latter
was particularly evident in cDC1s (Figure 2E). This is consistent
with the phenotype of resident cDCs in lymphoid organs, which
have higher CD11c and lower MHC class II surface levels than
migratory tissue-derived cDCs. Furthermore, cDC2s from
FL-Notch cultures showed induction of Esam, a marker of
NOTCH2-dependent splenic cDC2s (Figure 2F). Thus, DL1-
NOTCH2 signaling refines the phenotypes of BM-derived cDC
subsets and brings them closer to those of the primary resident
cDC in lymphoid organs.
The induction of CD8a on cDC1s and of Esam on cDC2s was
blocked by anti-N2 Ab (Figure 2G), confirming NOTCH2 as the
relevant receptor. Both DL1- and DL4-expressing OP9 cells
were able to induce differentiation of CD8a+ cDC1s; however,
DL1 induced higher levels of CD8a expression than DL4 (Figures
S2B and S2C). Addition of OP9-DL1 at an earlier (day 1) or later
(day 5) time point was less efficient (Figure S2D), suggesting that
a durable Notch signal delivered after the initial DC lineage
commitment provides optimal DC subset resolution.
As expected, global or DC-specific deletion of Irf8 spared
cDC2s, impaired pDCs, and fully abolished the development ofFigure 2. DL1-NOTCH2 Optimizes the Differentiation of cDC1s from th
Total murine BM cells were cultured in the presence of FLT3L alone (FL), FLT3L wi
DL1 (FL+Notch). OP9 cells were added on day 3, and BM cells were analyzed o
(A) Representative staining plots of differentiated BM cells. The top row shows tota
other rows show gated cDCs with CD11bhi cDC2s and/or CD11b cDC1s highlig
(B) The expression of CD8a on gated cDCs in BM cultures differentiated as in (A
(C) The subset composition of differentiated BM cells. Shown are fractions of pD
cDCs) and the absolute number of these subsets per 105 initial BM cells. cDC1s w
cultures of individual mice pooled from 2 experiments; bars represent mean.
(D) Representative expression of the indicated surfacemarkers on gated CD24+ cD
is included as a control.
(E) Representative expression of CD11c andMHC class II on DC subsets from FL
each case.
(F) Representative expression of Esam on cDC2s from FL or FL+Notch cultures.
negative staining.
(G) The effect of NOTCH2 blockade on the expression of CD8a on cDC1s and of
presence of control immunoglobulin G (IgG) or anti-N2; the fluorescence intensity
SD of 5 parallel cultures for anti-N2 and IgG and 9 cultures pooled from 2 experi
(H) The effect of transcription factor deletion on DC differentiation. BM from contr
knockout, cKO) or with germline deletion of Irf8 or Batf3 were cultured in FL or FL
live cells; data points represent values from individual mice pooled from three (fo
Statistical significance: ***p < 0.001, **p < 0.01, *p < 0.05.
3662 Cell Reports 23, 3658–3672, June 19, 2018cDC1-like cells in FL cultures (Figure 2H). On the other hand,
deletion of Batf3 only mildly affected cDC1FL development.
cDC1s in FL-Notch cultures showed the same strict dependence
on Irf8 but also a stronger dependence on Batf3 (Figure 2H).
Furthermore, Batf3 deletion reduced the expression of CD103
on cDC1s, as described previously (Jackson et al., 2011); this ef-
fect was particularly prominent in CD103hi cDC1FL-Notch (Fig-
ure S2E). Altogether, these results suggest that FL-Notch cul-
tures of primary BM yield cDC1 cells with the appropriate
phenotype and genetic requirements.
Notch Signaling Optimizes the Global Expression Profile
of In Vitro-Derived DCs
To further explore the effect of DL1-Notch signaling on in vitro-
derived DCs, we sorted cDC1s and cDC2s from FL and FL-
Notch cultures and interrogated their expression profiles by
global mRNA sequencing (RNA-seq). The resulting expression
profiles were merged with those of primary splenic cDCs (Lau
et al., 2016; Table S1) and compared using multidimensionality
scaling (MDS) analysis. As expected, the first dimension sepa-
rated culture-derived DCs from primary DCs (Figure S3A),
whereas the second and third dimensions separated DC subsets
(Figure 3A). By both the second and third dimension,
cDC2FL-Notch clustered closer than cDC2FL to primary cDC2
samples, particularly to the NOTCH2-dependent Esamhi subset
(Figure 3A). Moreover, cDC1FL-Notch clustered much closer to
primary cDC1 compared with cDC1-like cells from FL cultures
(Figure 3A).
Pairwise comparison between cDC1 and cDC2 for each cul-
ture condition showed a greater divergence of the two subsets
in FL-Notch cultures (Figure 3B). In particular, characteristic
markers of cDC1 (Xcr1, Clec9a, CD36, and Tlr11) and cDC2
(Itgam and Lyz2) showed greater differential expression. Pair-
wise comparison between FL and FL-Notch cultures for
each subset (Figure 3C; Table S2) showed that cDC2FL-Notch
induced the expression of NOTCH2-dependent genes overex-
pressed in Esamhi cDC2 (Lewis et al., 2011; Satpathy et al.,e BM
th control OP9 cells (FL+OP9) or FLT3L with OP9 cells expressing Notch ligand
n day 7 of differentiation.
l live cells with B220+ CD11clo pDCs and B220CD11chi cDCs highlighted; the
hted.
).
Cs (of total live cells) and cDC subsets (of gated B220 CD11c+ MHC class II+
ere defined either as CD24+ or CD8a+. Data points represent values from BM
C1s from FL or FL+Notch cultures. The expression of cDC1markers on cDC2s
or FL+Notch cultures. Subsets were gated, omitting the marker that is shown in
The expression on cDC1s is included as a control; the dotted line represents
Esam on cDC2s. BM cells were differentiated in FL or FL+Notch cultures in the
of marker expression in the indicated subsets is shown. Data represent mean ±
ments for controls.
ol wild-type (WT) mice or mice with DC-specific deletion of Irf8 (Irf8 conditional
-Notch cultures. Shown is the fraction of the indicated DC subsets among total
r Irf8) or two (for Batf3) experiments; bars represent mean.
Figure 3. Notch Signaling Optimizes the Expression Profile of BM-Derived DCs
Duplicate samples of sorted DC subsets from FL and FL-Notch cultures of primary BM were analyzed by RNA-seq.
(A) Multidimensionality scaling (MDS) analysis of RNA-seq profiles of DC subsets derived from FL cultures (DC1FL, DC2FL), FL+Notch cultures (DC1Notch,
DC2Notch), and primary splenic DC subsets fromWTmice (DC1WT, Esamhigh
WT, and Esamlow
WT DC2s). All samples are plotted on the second and third dimension
of MDS.
(B) Pairwise comparison of RNA-seq profiles of cDC1 versus cDC2 subsets from the indicated culture conditions. Shown are volcano plots of individual genes,
with select subset-specific marker genes highlighted.
(legend continued on next page)
Cell Reports 23, 3658–3672, June 19, 2018 3663
2013), including canonical Notch targets (Dtx1 and Hes1), char-
acteristic markers (Esam), and DC-specific Notch target genes
(Dnase1l3, Abcg3, Ffar2, and Gpr4). The downregulated
genes included markers of Esamlo cDC2 (Clec12a) and
multiple genes associated with other DC subsets, including
pDC (Siglech, Clec10a, and CD209d) and cDC1 (Xcr1, Clec9a,
CD36, Naaa, and Tlr11). In the pairwise comparison of cDC1,
the top upregulated gene was CD8a; other genes involved in
cDC1 function were upregulated (Il12b and Cd1d1), as were
DC-specific NOTCH2 targets (Dnase1l3, Abcg3, Ffar2, and
Gpr4). Of particular interest was the induction of genes control-
ling DC migration, including the actin-bundling protein Fscn1
(Yamashiro, 2012) and Ccr7, a receptor that guides DC migra-
tion from tissues to lymphoid organs (Worbs et al., 2017).
Conversely, downregulated genes included cDC2 and/or
myeloid markers (Lyz2, S100a9, and Itgam) and chemokine re-
ceptors that mediate DC migration from blood (Ccr1, Ccr2,
and Ccr5). Together with the phenotypic analysis, these data
show that Notch signaling optimizes DC subset-specific gene
expression and drives their differentiation toward their in vivo
counterparts.
Finally, we tested whether induced Notch signaling in culture
recapitulates the Notch-dependent gene expression program
of primary splenic DCs. We compiled genes that were differen-
tially expressed in NOTCH2-deficient splenic cDC1, cDC2,
or both subsets (Satpathy et al., 2013) and analyzed their
expression in culture-derived and primary cDC (Table S3). The
expression of both NOTCH2-induced genes (Figure 3D) and
NOTCH2-repressed genes (Figure S3B) faithfully clustered
cDC1FL-Notch and cDC2FL-Notch with their primary counterparts,
whereas cDC1FL and cDC2FL clustered separately from primary
cDCs. Both subsets showed upregulation of subset-specific and
common Notch target genes, including the abovementioned
Dnase1l3, Abcg3, Ffar2, Gpr4, Esam, and Dtx1 (Figure 3D).
Notably, cDC1-enriched Notch target genes included CD8a,
Fscn1, and Ccr7, suggesting that their induction in cDC1FL-Notch
reflects their natural regulation byNotch. Conversely, downregu-
lated genes repressed by Notch included progenitor genes (e.g.,
CD34 and Cx3cr1), subset-inappropriate genes (e.g., Tlr4 in
cDC1 and CD36 in cDC2), and chemokine receptor Ccr2
(Figure S3B). Thus, OP9-DL1 co-cultures facilitate cDC differen-
tiation by recapitulating the physiological Notch-dependent
gene expression program of primary cDCs.
Notch Signaling Optimizes Migratory Properties of
In Vitro-Derived DCs
We examined the distinct functional properties of cDC1s from FL
and FL-Notch cultures in vitro. Despite the increased baseline
expression of Il12b (Figure 3C), cDC1FL-Notch did not show an
enhanced interleukin-12 (IL-12) response to the TLR11 ligandpro-
filin (datanot shown).Cross-presentationofexogenousproteinAg
to CD8+ T cells is a hallmark property of cDC1 (den Haan et al.,(C) Pairwise comparison of RNA-seq profiles of the indicated DC subsets generate
with select highly differentially expressed genes highlighted.
(D) Heatmap of Notch-dependent gene expression in cultured and primary DC sub
of genes that were downregulated preferentially in Notch2-deficient cDC1s, cDC
represents the row Z score.
3664 Cell Reports 23, 3658–3672, June 19, 20182000; Hildner et al., 2008). To measure Ag cross-presentation
in vitro, we pulsedDCs from either culturemethodwith ovalbumin
(OVA),washedand incubated themwithH-2Kb-OVApeptide-spe-
cific T cell receptor (TCR) transgenic OT-I CD8+ T cells, and
measured OT-I proliferation by the dilution of the cell tracer dye
carboxyfluorescein succinimidyl ester (CFSE). Total DCs and en-
riched cDC1s fromboth culture types induced comparably strong
OT-I proliferation at a 1:1DC:T cell ratio (data not shown). At lower
DC:T cell ratios (1:5–1:10), total DCs and enriched cDC1s from
FL-Notch cultures induced more extensive CFSE dilution in
T cells (Figures 4A and 4B). Thus, Notch signaling is not strictly
required for the cross-presenting capacity of cDC1 but facilitates
T cell cross-priming under limiting conditions in vitro.
Comparison of DCFL and DCFL-Notch expression profiles iden-
tified regulators of cell migration among the most differentially
expressed genes (Figures 3C and 3D). We therefore analyzed
the expression of chemokines and their receptors in culture-
derived and primary DCs (Table S4). Unsupervised clustering
by chemokine expression did not group DCFL-Notch with primary
DCs (Figure S3C). Nevertheless, several chemokines were
induced in cDC1FL-Notch compared with cDC1FL, including
Cxcl9 (Figure S3D). Notably, CXCL9 is preferentially expressed
in primary cDC1s (Figure S3D) and plays a major role in cDC1-
mediated priming of tumor-specific T cell responses (de Mingo
Pulido et al., 2018; Spranger et al., 2017). The expression of che-
mokine receptors separated DCFL from other samples but clus-
tered DCFL-Notch with their respective splenic DC counterparts
(Figure 4C). Furthermore, cDC1FL-Notch showed a profound
downregulation of Ccr1, Ccr2, and Ccr5 and induction of Ccr7,
aligning the expression of these receptors with primary cDC1
(Figure 4D). The induction of Ccr7 in cDC1FL-Notch was particu-
larly notable given its very low levels in cDC1FL. Cell surface
staining confirmed the induction of CCR7 expression on
DCFL-Notch (Figure 4E). Accordingly, transwell migration assays
showed that all DCFL preferentially migrated toward the CCR2
ligand CCL2, with lower migration toward the CCR1 and CCR5
ligand CCL5 and CCR7 ligand CCL19 (Figure 4F). In contrast,
DCFL-Notch failed to migrate toward CCL2 or CCL5, but showed
increased migration toward CCL19, with the difference being
particularly notable in the cDC1 subset (Figure 4F). These data
suggest that Notch signaling induces a more physiological
pattern of chemokine receptor expression and migration in
cultured DCs, specifically favoring CCR7-dependent over
CCR2- and CCR5-dependent migration.
Notch Signaling Facilitates cDC1-Mediated T Cell
Cross-Priming and Antitumor Vaccination
Given the optimized cross-presenting and migratory proper-
ties of DCFL-Notch in vitro, we tested the ability of these cells
to cross-prime T cell responses in vivo. DCs from FL or
FL-Notch cultures were pulsed with OVA, and either total
DCs or enriched CD24+ cDC1s (Figure S4A) were transferredd in FL versus FL-Notch cultures. Shown are volcano plots of individual genes,
sets. Samples (labeled as in A) were hierarchically clustered by the expression
2s, or both cDC1s and cDC2s. Select genes are highlighted; the color scale
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B Figure 4. Notch Facilitates CCR7-Depen-
dent Migration of DCs
DCs were generated by culturing murine BM cells
in the presence of FLT3L alone (FL) or FLT3L with
OP9 cells expressing the Notch ligand DL1
(FL+Notch).
(A and B) Cross-priming of CD8+ T cells in vitro. FL
or FL-Notch cultures on day 7 were incubated with
OVA, and either total cultures or enriched cDC1s
were incubated with CFSE-labeled OT-I cells at a
1:10 ratio for 3 days.
(A) The levels of CFSE versus the activation marker
CD44 in gated CD8+ T cells from cultures with
the indicated DCs, with the individual peaks of
CFSE dilution highlighted. No CFSE dilution was
observed in the absence of OVA (data not shown).
(B) The fraction of T cells in each peak (mean of 4
parallel cultures ± S.D., representative of 2 exper-
iments).
(C) Unsupervised clustering of cultured and pri-
mary splenic DCs by the expression of chemokine
receptors (Table S4). Shown is the clustering
dendrogram with individual replicates of the indi-
cated samples.
(D) Heatmap of select chemokine receptor
expression in cultured and primary splenic DCs as
determined by RNA-seq. The color scale repre-
sents the row Z score.
(E) The expression of CCR7 on the surface of cul-
ture-derived DCs. Shown is a representative
staining profile and averaged mean fluorescence
intensity (MFI) of CCR7 on gated CD11b+ cDC2s or
CD24+ cDC1s. Data represent mean ± range of 2
cultures.
(F) DC migration in vitro in a transwell assay. Total
DCs from FL or FL+Notch cultures were seeded in
top chambers with the indicated recombinant
chemokine in the bottom chamber and allowed to
migrate for 3 hr. Shown is the fraction of each DC
subset that migrated into the bottom chamber.
Data represent mean ± SD of 4 parallel transwell
cultures, representative of 3 experiments.
Statistical significance: *p < 0.05.into wild-type syngeneic H-2Kb recipients. One week later,
OVA-specific endogenous CD8+ T cells were detected with
an H-2Kb-OVA peptide (SIINFEKL) tetramer. We found that
up to 106 cells/animal of DCFL failed to elicit OVA-specific
T cells in the spleen (Figure S4B) and in the peripheral blood
(Figures 5A and 5B). In contrast, DCFL-Notch induced robust
T cell responses even at lower doses (0.25–0.5 3 106 cells/an-
imal) (Figure S4B; Figures 5A and 5B). Furthermore, a majorCell Rimprovement in T cell priming was also
observed when the same experiments
were done with enriched cDC1FL-Notch
(Figures 5A and 5C). The comparison of
total DCs to cDC1s in these experiments
was confounded by the cDC1 isolation
procedure and by potential saturation
of the T cell response. Nevertheless, it
is notable that neither total DCFL nor en-
riched cDC1FL could cross-prime at anydose, whereas total DCFL-Notch and cDC1FL-Notch were compa-
rably efficient.
To test the consequences of differential T cell priming, recip-
ient mice were challenged with the OVA-expressing syngeneic
melanoma cell line B16 (B16-OVA). After intravenous (i.v.)
retroorbital administration of 2.5 3 105 B16-OVA cells, all un-
treated mice became moribund with respiratory distress within
2 weeks and had to be sacrificed (Figure 5D). Histologicaleports 23, 3658–3672, June 19, 2018 3665
Figure 5. Notch Facilitates cDC1-Mediated T Cell Cross-Priming In Vivo
DCs from FL or FL+Notch cultures of primary murine BM were incubated with OVA, and total DCs or enriched cDC1s were injected i.v. into naive WT syngeneic
recipient mice. The priming of endogenous OVA peptide-specific CD8+ T cells was determined 7 days later by staining of PB leukocytes with H-2Kb-OVA peptide
tetramer.
(A) Representative staining profiles of gated CD44+ TCRb+-activated T cells in the PB, with the CD8+ tetramer+ cells highlighted.
(B) The fraction of OVA-specific T cells among total CD44+ TCRb+ CD8+ cells after vaccination with the indicated numbers of total DCs. Mice that received no
injection (control) or a mock PBS injection are shown as well. Data points represent values from individual mice pooled from 2 experiments; bars represent mean.
(C) The fraction of OVA-specific T cells after vaccination with 3 3 105 enriched cDC1s. Data points represent values from individual mice pooled from 3 ex-
periments; bars represent mean.
(D) Kaplan-Meier survival plot of animals that were vaccinated with OVA-pulsed total DCs and subsequently challenged with the OVA-expressing melanoma
cell line.
Statistical significance: ****p < 0.0001, ***p < 0.001.analysis of the lungs showed disseminated infiltration of the alve-
olar space by B16 cells, likely causing respiratory failure (Fig-
ure S4C). A similar mortality was observed in all mice vaccinated
with OVA-pulsed total DCFL (Figure 5D). In contrast, vaccination
with OVA-pulsed total DCFL-Notch conferred near-complete pro-
tection against B16-OVA challenge (Figure 5D). The single
DCFL-Notch recipient that succumbed to the tumor harbored a
low fraction (<0.2%) of OVA-specific T cells, confirming the
dependence of protection on T cell priming. We also performed
these experiments injecting B16-OVA cells i.v. through the tail
vein; this route of administration yielded the characteristic focal
growth of melanoma cells in the lungs. Again, vaccination with
OVA-pulsed DCFL had no effect, whereas vaccination with
DCFL-Notch strongly reduced the growth of melanoma foci (Fig-
ure S4D). We conclude that FL-Notch culture generates cDC1s
with a superior capacity for T cell cross-priming and antitumor
vaccination.
Notch Signaling Facilitates Development of cDC1s from
Human Hematopoietic Progenitors
The potential therapeutic properties of cDC1s, but their rarity
in vivo, led us to explore in vitro differentiation approaches in hu-3666 Cell Reports 23, 3658–3672, June 19, 2018mans. Culture of BM CD34+ progenitors in liquid medium sup-
plemented with the cytokines FLT3L, stem cell factor (SCF),
and GM-CSF (FSGM) generated only CD14+ and CD1c+ mono-
cyte-like or cDC2-like cells (Figure 6A). Addition of anOP9 feeder
layer supported the simultaneous generation of all three DC sub-
sets with a low yield of 0.4 cDC1s per input CD34+ progenitor
(Figure 6B). Addition of a Notch signal by co-culture with OP9-
DL1 cells resulted in selective expansion of cDC1s, increasing
the cDC1 output 11-fold (4.4 cDC1s per input progenitor) on
day 14 of culture. A lower expansion of cDC1s (2.8 cDC1s/pro-
genitor) was seen on exposure of progenitors to OP9-DL4 under
similar culture conditions (Figures 6A and 6B). cDC1 expansion
was dependent on a continuous Notch signal because with-
holding or withdrawing Notch ligand for the first or last 7 days,
respectively, decreased the effect (Figure S5A).
Culture-generated cDC1s expressed the human cDC1-spe-
cific markers CD141 and CLEC9A at levels comparable with or
higher than ex vivo blood cDC1s (Figure S5B). However, they ex-
pressed low levels of CD11c and high levels of CD1c, differing
from peripheral blood (PB) cDC1s but resembling the phenotype
of peripheral tissue cDC1s (Figure S5B). Next we performed a
gene expression analysis on the NanoString nCounter platform
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Figure 6. Notch Facilitates cDC1 Development from Human BM Progenitors
(A and B) Sorted CD34+ stem and progenitor cells purified from human BMwere cultured for 2 weeks in the presence of a FLT3L-containing cytokine mix (FSGM)
or on monolayers of control OP9, OP9-DL1, or OP9-DL4 cells.
(legend continued on next page)
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running the Human Immunology v2 panel (594 genes) with the
addition of 30 DC-specific genes (Table S5). Expression profiles
were compared after removal of the genes with low expression
levels and of the genes that were differentially expressed be-
tween all culture and all ex vivo subsets (the cell culture signa-
ture). By subsequent principal-component analysis based on
339 genes, the first component separated pDCs from cDCs
and the second cDC1s from cDC2s (Figure 6C). Notably, OP9-
DL1-differentiated cDC1s grouped closely with OP9-derived
cDC1s and with primary cDC1s from the PB. Accordingly, genes
encoding subset-specific transcription factors, surface markers,
and TLRs were expressed faithfully, including CLEC9A, XCR1,
TLR3, IRF8, and BATF3 in cDC1s (Figure S5C). The expression
of chemokine receptors was similarly segregated by subset (Fig-
ure S5D), although a higher expression of CCR7 in OP9-derived
cDC1s and cDC2swas noted. In contrast, the expression of che-
mokines segregated OP9-derived cDC1s and cDC2s, which
showed higher levels of CXCL10, CXCL12, and CCL22 than
either DL1-derived DCs or primary DCs (Figure S5E). Thus, un-
like in the mouse system, OP9-DL1 does not appear to affect
the overall expression profile or the expression of migration reg-
ulators in cDC1s. Nevertheless, we conclude that DL1-induced
Notch signaling greatly increases the number of differentiated
cDC1s with the appropriate expression profile.
Biallelic IRF8 mutation in human abrogates pDC, cDC1, and
cDC2 development in vivo (Bigley et al., 2017; Hambleton et al.,
2011). To interrogate the IRF8 requirement for in vitro Notch-
induced cDC1 expansion, IRF8108E/108E and IRF883C/291Q
CD34+ progenitors were co-cultured with either OP9 or OP9-
DL1. cDC1s and pDCs failed to emerge under either condition,
whereas some cDC2 generation was observed (Figures 6D and
6E). Thus, Notch signaling from DL1 specifically facilitates the
development of human cDC1s with the appropriate phenotype,
expression profile, and genetic requirements.
Notch-Driven Differentiation Results in Functional
Human cDC1s
To interrogate the functional capacity of in vitro-generated DCs,
we examined cytokine production in response to TLR agonists.
PB mononuclear cells or in vitro-derived DCs were exposed to
a cocktail of TLR agonists (CL075, CpG, lipopolysaccharide
[LPS], and poly-I:C), and subset-specific cytokine production
was assessed by intracellular flow cytometry (Figures 7A and
7B). Tumor necrosis factor (TNF) production by cDC1s was
significantly increased in OP9-DL1-derived compared with
OP9-derived cells and comparable with blood cDC1s. No sig-
nificant increase in IL-12 production was observed in cDC1s
or cDC2s generated in vitro, but a decrease in both TNF(A) Representative staining profiles highlighting the indicated DC subsets in the res
represent the percentage of gated cells.
(B) Absolute numbers of DC subsets generated in a 0.2-mL culture standardized to
from different donors (n = 8 for OP9, 7 for OP9-DL1, and 2 for OP9-DL4); bars rep
tailed t test. The data represent the absolute number of DC subsets per input pr
(C) Comparison of expression profiles of culture-derived and primary DC subsets
analysis of the indicated triplicate samples after removal of the ‘‘culture signature
(D and E) Representative staining profiles (D) and cell yields (E) of the cultures
IRF883C/291Q). The experiments were done as in (A) and (B).
3668 Cell Reports 23, 3658–3672, June 19, 2018and interferon a (IFN-a) was observed in DL1-derived pDCs
(Figure 7B).
Culture-derived cDC1s showed appropriate migration in a
transwell assay toward the XCR1 ligand XCL1 as well as weaker
migration toward CCR2, CCR5, and CCR7 ligands; no major dif-
ferences between OP9- and OP9-DL1-derived DCs were noted
(data not shown). To assess their T cell-stimulatory capacity,
cDC1s and cDC2s from the PB or from in vitro cultures were
sorted and co-cultured with allogeneic T cells. The proportion
of CD4+ or CD8+ T cells that underwent division was determined
by CFSE dilution (Figure 7C). It should be noted that no differ-
ences were expected between CD4+ and CD8+ T cells in this
assay, which measures direct T cell activation rather than
cross-priming. cDC1s generated on OP9-DL1 stimulated prolif-
eration in a significantly greater proportion of both CD4+ and
CD8+ T cells compared with those generated on OP9; this effect
was not observed in cDC2s (Figure 7D). We conclude that Notch
signaling induces the development of functionally intact cDC1s,
which show a significant improvement in their in vitro T cell prim-
ing capacity. Together with the drastic increase of cDC1 yield,
these data underscore the improvement of cDC1 generation in
Notch-driven cultures.
DISCUSSION
We describe an in vitro method of DC generation based on the
combination of two cell-extrinsic signals, FLT3L and Notch.
FLT3L is the key cytokine for the DC lineage and alone is suffi-
cient to drive DC development and subset specification from
murine hematopoietic progenitors. Murine FLT3L-derived
cDCs harbor a population of IRF8-dependent cDC1-like cells
(cDC1FL) that manifest functional hallmarks of cDC1s, such as
IL-12 production and T cell cross-priming in vitro (Naik et al.,
2005). However, these cells have an abnormal CD11b+ CD8a
Dec205 CD103 phenotype, fail to migrate toward CCR7,
and are shown here to have a poor capacity for T cell cross-prim-
ing in vivo. A combination of FLT3L with the cytokine GM-CSF in
a two-step culture selectively expands cDC1-like cells and con-
fers CD103 expression, yielding so-called iCD103-DCs (Mayer
et al., 2014). However, iCD103-DCs have the same aberrant
CD11b+ CD8a Dec205low phenotype and lack CCR7 expres-
sion unless stimulated with TLR ligands. Moreover, their expres-
sion profile and functional properties were never directly
compared with those of cDC1FL, and their T cell priming capacity
in vivowas tested only after TLR-induced activation (Mayer et al.,
2014). Thus, apart from the expected induction of CD103 (Zhan
et al., 2011), GM-CSF does not appear to improve the quality of
FLT3L-derived cDCs. Conversely, stromal cells expressing theulting cultures; primary DCs from the PB are included for comparison. Numbers
3,000 CD34+ progenitor cell input. Data points represent values in BM cultures
resent mean with SEM. The indicated p values were derived by unpaired two-
ogenitor cell.
based on the Nanostring nCounter analysis. Shown is the principal-component
’’ derived by pairwise comparison of all culture-generated versus ex vivo cells.
of BM from the two patients with biallelic IRF8 mutations (IRF8108E/108E or
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Figure 7. Notch-Driven Differentiation Yields Functional Human cDC1s
DCs generated from CD34+ progenitors in cultures with OP9 or OP9-DL1 were analyzed in parallel to primary DCs from PB.
(A and B) Cytokine production by DCs stimulated for 14 hr with a cocktail of TLR agonists (poly-I:C, LPS, CL075, and CpG).
(A) Representative flow cytometric analysis of intracellular cytokine production (TNF, IL-12, and IFN-a) in the indicated gated DC subsets fromOP9-DL1 cultures.
Grey contours represent unstimulated cells; numbers represent the cytokine-positive fraction.
(B) Proportion of cytokine-positive cDC1s (purple), cDC2s (red), or pDCs (blue) generated from CD34+ progenitors in culture with OP9 (n = 4) or OP9-DL1 (n = 3)
cells compared with PB primary (n = 7) cells following TLR stimulation. Circles, histograms, and bars represent individual experiments, mean, and SEM,
respectively; p values are indicated.
(C and D) T cell stimulation by DCs cultured with sorted allogeneic blood CD3+ T cells.
(C) Representative flow cytometric analysis of T cell proliferation in response to culture with DCs. The data show output of a T cell and cDC1 (generated with OP9-
DL1) culture. CD11c+ CD141+ cDC1s could be identified (purple gate) and gated out. CD3+ T cells were subdivided by CD8 and CD4 expression. Cell division was
indicated by CFSE dilution (turquoise gate).
(D) Proportion of CD4+ or CD8+ T cells that underwent division (CFSE dilution) in culture with cDC1 (purple) or cDC2 (red) isolated from PB or generated in culture
with OP9 or OP9-DL1 (DL1) cells. T cells cultured alone or with beads coated with anti-CD3 plus anti-CD28 were used as negative (Neg) and positive (Pos)
controls, respectively. Responses to blood DCs were generated from 2–3 DC donors and 3 T cell donors (2–6 independent experiments). Responses to cultured
DCs were generated from 2 BM donors combined with 3 T cell donors (4–6 independent experiments). Each circle represents an independent experiment
(mean of 1–3 technical replicates). Histograms and bars represent mean and SEM, respectively. The p values were derived from unpaired two-tailed Student’s
t test.Notch ligand DL1 were reported to improve DC differentiation in
GM-CSF cultures, but these do not generate any cDC1 output
(Cheng et al., 2007).Here, we show that the introduction of the Notch ligand DL1
into FLT3L-driven culture using the OP9-DL1 stromal cell line
(Schmitt et al., 2004) yields the two main cDC subsets, includingCell Reports 23, 3658–3672, June 19, 2018 3669
bona fide CD11b CD8a+ Dec205+ CD103+ cDC1s. Indeed,
cDC1s and cDC2s becamemore distinct by key surfacemarkers
and by global expression profile, at the same time better resem-
bling their primary counterparts in the spleen. Notably, cDC2s
showed higher similarity to the Esamhi subset of splenic
cDC2s, which manifest a superior ability to prime T cells (Lewis
et al., 2011). Most importantly, the cDC1 subset manifested
the appropriate surface phenotype and expression profile and
an improved ability to cross-prime CD8+ T cell responses. The
latter underscores a dramatic improvement in the quality of re-
sulting cDC1s, even as the fraction and numbers of cDC1s
were not increased. Indeed, Notch-derived cDC1s dramatically
outperformed conventional cDC1-like cells in T cell priming
in vivo, even atmuch lower numbers.Moreover, the potential lim-
itation of cell numbers can be overcome by our system’s appli-
cation to immortalized DC progenitors, which can be scaled up
indefinitely.
The improved functionality of Notch-derived cDC1s does not
appear to reflect an effect on Ag cross-presentation capacity
per se because cDC1-like cells fromFL cultures could cross-pre-
sent in vitro, as described previously (Naik et al., 2005). Instead, it
is likely due to an enhanced capacity to recruit T cells (e.g.,
through the elevated expression of CXCL9) and/or to migrate to-
ward appropriate locations in lymphoid organs. These functions
are less important when DCs and T cells interact in the artificial
context of in vitro cultures (except at lower DC:T cell ratios) but
are critical for T cell priming in vivo. FL-Notch co-cultures
switched the chemokine receptor expression pattern of the re-
sultingDCs fromCCR1,CCR2, andCCR5 towardCCR7, recapit-
ulating that of DCs in lymphoid organs. This switch facilitated the
migration towardCCR7 ligands, the process that guidesDCs into
T cell zones and is essential for T cell priming in vivo (Worbs et al.,
2017). Collectively, Notch signaling increases the similarity of
in vitro-generated DCs to their primary counterparts in the
lymphoid organs, optimizing the functional properties of cDC1s.
Notch signaling is important for the differentiation of cDC2s in
the spleen and intestine; indeed, these cells expressNotch target
genes such as Hes1 and Dtx1, are located in DL1-expressing
splenic niches, and depend on NOTCH2 and the canonical
RBPJ-mediated signaling downstream of it (Caton et al., 2007;
Lewis et al., 2011). In contrast, cDC1s express few or no Notch
target genes and are unaffected by DC-specific loss ofRbpj (Ca-
ton et al., 2007); however, Notch2 deletion impairs their pheno-
type and expression profile (Lewis et al., 2011; Satpathy et al.,
2013). Consistent with the latter observation, our results identify
the DL1-NOTCH2 axis as a signal that is missing in conventional
FLT3L cultures and whose induction can drive differentiation into
authentic functional cDC1s. To reconcile these data, we propose
that DL1-NOTCH2 signaling is an important extrinsic signal for
cDCs in the spleen (and possibly other lymphoid organs) that
acts on committed cDC progenitors to facilitate cDC1 and
cDC2 subset specification and terminal differentiation. This
signal then stays ‘‘on’’ in Esamhi cDC2, which remain in contact
with DL1-expressing stroma and are fully dependent on DL1
signaling through NOTCH2-RBPJ for their survival. In contrast,
the DL1-NOTCH2 signal may be turned ‘‘off’’ as cDC1s migrate
throughout the spleen and lose Notch target gene expression
and NOTCH2-RBPJ dependence. Overall, our studies empha-3670 Cell Reports 23, 3658–3672, June 19, 2018size the critical role of Notch signaling in the functional differenti-
ation of both cDC subsets and demonstrate its utility to facilitate
cDC generation in vitro.
FLT3L alone appears to be insufficient to drive DC develop-
ment from human hematopoietic progenitors and has to be sup-
plemented with other cytokines (Balan et al., 2014; Poulin et al.,
2010; Proietto et al., 2012) or stromal cell lines, including MS5
alone (Lee et al., 2015) or a mixture of MS5 and OP9 (Lee
et al., 2017). These conditions can generate mature CD141+
cDC1s with the appropriate phenotype, expression profile,
and in vitro functionality. However, the fraction and absolute
numbers of the resulting cDC1s are low in all cases, hampering
their detailed functional characterization and practical use. This
situation appears to be different from that in the mouse, where
FLT3L alone can drive the development of abundant but not fully
mature cDC1-like cells. It was recently reported that co-culture
of human thymic progenitors with OP9-DL1 blocked the emer-
gence of DC progenitors but increased the yield of cDCs from
the latter (Martı´n-Gayo et al., 2017); neither the net effect on
DC development nor the resulting DC phenotypes were investi-
gated.We report that, although co-culture of human BMprogen-
itors with OP9 generates all DC subsets, addition of the Notch
ligand DL1 resulted in a more than 10-fold increase in cDC1
output per progenitor cell. The resulting cDC1s aligned closely
with their ex vivo counterparts by gene expression analysis,
were strictly IRF8-dependent, and showed increased T cell-
stimulatory capacity. In contrast to mouse BM cultures, DL1
was required continuously from the beginning of the culture;
furthermore, unlike in the mouse system, no major effects of
DL1 on the phenotype, expression profile, or migration of the re-
sulting cDC1s were noted. This may reflect different compara-
tors for OP9-DL1 cultures (‘‘FLT3L only’’ in the mouse and
‘‘FLT3Lwith other cytokines andOP9’’ in the human); differences
in the effect of murine OP9 cells and their products (cytokines,
adhesion molecules) on murine versus human cells; and/or bio-
logical differences between the two species. In each case, how-
ever, Notch signaling appeared to solve a major hurdle to cDC1
differentiation; i.e., it improve the suboptimal expression profile
and functionality in the mouse and increase low numbers in hu-
mans. Collectively, these results emphasize the conserved pos-
itive effect of Notch signaling on in vitro cDC1 differentiation.
The long-standing idea of DC-based vaccination against tu-
mors (Palucka and Banchereau, 2013) is now being actively pur-
sued in human patient studies, especially in combination with
other immunotherapies (Garg et al., 2017). cDC1s appear to
play a particularly important role in antitumor responses through
their efficient cross-priming of tumor-specific cytotoxic T cells
(Bottcher et al., 2018; Roberts et al., 2016; Salmon et al., 2016;
Spranger et al., 2017). The utility of cDC1s for antitumor vaccina-
tion is further illustrated by our results in the mouse, in which
Notch-derived cDC1s protected against tumor challenge
whereas larger numbers of total FL-derived DCs did not. The util-
ity of human cDC1s for antitumor vaccination so far has been
severely limited by their rarity in vivo and low yield in vitro. Our
system overcomes this hurdle by increasing the output of human
cDC1s by an order of magnitude, facilitating their potential use
for vaccination. Notably, Notch-derived cDC1s are functional
in vivo without prior TLR-induced activation, an important
advantage for translational applications. Furthermore, the acti-
vation-independent functionality of Notch-derived DCs supports
their potential application for tolerogenic DC vaccination; e.g.,
against autoimmune diseases. Collectively, the methods of
in vitro DC generation described here should facilitate mecha-
nistic and translational studies focused on the therapeutic po-
tential of DCs.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human studies
The study was performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from participants
prior to recruitment. The study was approved by NRES Committee North East-Newcastle and North Tyneside (08/H0906/72, 14/NE/
1212 and 14/NE/1136). Peripheral blood or bone marrow was obtained from healthy volunteers or from the previously described pa-
tients with biallelic IRF8 mutations (Bigley et al., 2017; Hambleton et al., 2011).Cell Reports 23, 3658–3672.e1–e6, June 19, 2018 e3
Animals
All animal studies were performed according to the investigator’s protocol approved by the Institutional Animal Care and Use Com-
mittees of New York University School of Medicine and of Columbia University Medical Center. Wild-type C57BL/6 mice (Jackson
Laboratories) and Rag2-deficient OT-I TCR transgenic mice (Rag2/OT-I, Taconic) were maintained by intercrossing in the animal fa-
cility at New York University School of Medicine. Mice deficient for Batf3 (Hildner et al., 2008) or Irf8 (Ouyang et al., 2011), mice with a
conditional LoxP-flanked allele of Irf8 (Irf8flox) (Feng et al., 2011) and the Itgax-Cre deleter strain (Caton et al., 2007) have been
described previously and were on pure C57BL/6 background. Irf8flox and Itgax-Cre mice were intercrossed to obtain Irf8flox/flox
Itgax-Cre+ mice with a specific deletion of Irf8 in CD11c+ cells. Mice were group-housed in individually ventilated cages and main-
tained under specific pathogen-free conditions. Male and female mice were used between 8 and 16 weeks of age. No obvious dif-
ference between sexes was observed within the parameters analyzed for our experiments.
Cell lines
FLT3L-secreting (Mach et al., 2000) and OVA-expressing (Falo et al., 1995) clones of the C57BL/6-derived B16 melanoma cell line
(B16-FLT3L andB16-OVA, respectively) were cultured in DMEMmedium supplemented with 10% fetal calf serum (FCS), 1%L-gluta-
mine, 1% sodium pyruvate, 1% MEM-NEAA and 1% penicillin/streptomycin (full DMEM) at 37C in a humidified atmosphere at 5%
CO2. The murine progenitor Hoxb8-FL cell line (Redecke et al., 2013) was cultured in RPMI medium supplemented with 10% FCS,
1% L-glutamine, 1% penicillin/streptomycin, 10% supernatant from cultured B16-FLT3L cell line and 1 mm b-estradiol at 37C in a
humidified atmosphere at 5% CO2. For differentiation, Hoxb8-FL cells were cultured in the same medium without estradiol and with
charcoal-stripped FCS to ensure the absence of estradiol. OP9 cell lines transduced with retroviruses encoding green fluorescent
protein (GFP) or Notch ligands DL1 or DL4 (Mohtashami et al., 2016; Schmitt et al., 2004) were cultured in MEM-a medium supple-
mented with 20% FCS and 1% penicillin/streptomycin (OP9 medium) at 37C in a humidified atmosphere at 5% CO2. Prior to use in
co-cultures, OP9 cells were treated with mitomycin C at 10 mg/mL for 2 hr, harvested, washed three times in PBS and resuspended in
OP9 medium. For co-culture with human cells, OP9 were maintained in MEM-a supplemented with 10% FCS and 1% penicillin/
streptomycin.
METHOD DETAILS
Methods: mouse
Cell preparations
Spleens were minced and digested with collagenase D (1 mg/mL) and DNase I (20 mg/mL) in full DMEM for 30 min at 37C. Tissues
were pressed through a nylon 70 mm cell strainer to yield single-cell suspensions and then subjected to red blood cell (RBC) lysis
(155 mM NH4Cl, 10 mM NaHCO3, 0.1 mM EDTA) for 5 min at room temperature before being filtered. Bone marrow (BM) was pre-
pared by flushing femurs and tibias with phosphate buffer saline (PBS) using a 27-gauge needle followed by RBC lysis and filtering
through a sterile 70 mm cell strainer. Peripheral blood (PB) was obtained by submandibular bleed and subjected to RBC lysis for
5 minutes, followed by 3 min, at room temperature (RT).
Flow cytometry
Single-cell suspensions of cultured DCs or primary cells were stained for multicolor analysis with the indicated fluorochrome- or
biotin-conjugated antibodies. Antibodies were diluted in FACS buffer (PBS, 1% FCS, 0.02% NaN3). With the exception of Hoxb8-
derived DCs, staining of surface molecules with fluorescently labeled antibodies was performed for 20 min at 4C in the dark.
Hoxb8-derived DCs were stained at room temperature. For in vivo cross-presentation experiments, the OVA peptide/H-2Kb tetramer
was used and staining was performed for 30 min at room temperature. Samples were acquired on LSR II (BD) flow cytometer using
FACSDiva software (BDBiosciences) or AttuneNxT (Invitrogen) using AttuneNxT software and further analyzedwith FlowJo software
(Tree Star).
FLT3L-driven DC differentiation of Hoxb8-FL cultures
Hoxb8-FL progenitor cells were expanded in culture and differentiated as previously described (Grajkowska et al., 2017; Redecke
et al., 2013). Briefly, progenitor cells were removed from b-estradiol-supplemented medium and washed three times in PBS with
10% charcoal-stripped FBS at room temperature. The cells were then plated in fresh medium without estradiol at 2x105 cells per
well in 6-well plates and cultured for 7 days without replating.
Notch-driven DC differentiation of Hox8-FL cultures
FLT3L-driven Hoxb8-FL DC differentiation was initiated as described above. On day 3 of differentiation, cells were harvested and
resuspended in fresh medium. The cells were then plated at 2.5x105 cells per well in 24-well plates containing a monolayer of mito-
mycin-treated OP9-DL1 cells. Where indicated, control OP9-GFP or OP9-DL4 cells were used in a similar fashion. For NOTCH2
blocking experiments, cells were treated with anti-NOTCH2 antibody or control IgG (50 ng/mL or 500 ng/mL) on day 3 at the time
of co-culture initiation. Cell cultures were analyzed by flow cytometry on day 7.
FLT3L-driven DC differentiation of primary BM cultures
Single cell suspensions of primary murine BM cells were obtained as described above. The cells were suspended in DMEM
medium supplemented with 10% FCS, 1% L-glutamine, 1% sodium pyruvate, 1% MEM-NEAA and 1% penicillin/streptomycin,
55 mM 2-mercaptoethanol and, 10% supernatant from cultured B16-FLT3L cell line (DC medium). Cells were plated at 2x106 cellse4 Cell Reports 23, 3658–3672.e1–e6, June 19, 2018
per well in 2 mL of DC medium in 24-well plates and cultured at 37C in a humidified atmosphere at 5% CO2 for 7 days without
replating.
Notch-driven DC differentiation of primary BM cultures
Primary BMcultures were initiated as described above. On day 3 of differentiation, half of the volume of cells in DCmedium from each
well was transferred to a single well containing a monolayer of mitomycin-treated OP9 cells in 24-well plates. Where indicated, con-
trol OP9-GFP or OP9-DL4 cells were used in a similar fashion. For NOTCH2 blocking experiments, cells were treated with anti-
NOTCH2 antibody or control IgG at various concentrations on day 3 at the time of coculture initiation. Cell cultures were analyzed
on day 7.
In vitro DC migration assay
DC migratory capacity was evaluated using a transwell assay using 24-well plates of 6.5 mm transwells with 5.0 mm pore polycar-
bonate membrane (Corning). Cultured DCs were harvested on day 7 and resuspended in DMEM medium supplemented with
2% FCS, 1% L-glutamine, 1% sodium pyruvate, 1% MEM-NEAA and 1% penicillin/streptomycin (migration medium) at
5 3 105 cells/ml. Migration medium containing chemokines (100 ng/mL in 0.6 mL total volume) was placed at the bottom of each
well. DC suspension (100 mL) was added to the top chamber and incubated at 37C in a humidified atmosphere at 5% CO2 for
3 hr. Migrated cells at the bottom of the wells were recovered in 500 mL of cold PBS supplemented with 2% FBS and 0.5 mM
EDTA and analyzed by flow cytometry. For each DC type, frequency of migrated cells was calculated as # cells migrated out of total
input per DC type as determined flow cytometry.
In vitro T cell stimulation
Endotoxin-free chicken ovalbumin (OVA) protein (Sigma Aldrich) was added to DC cultures on day 7 to a final concentration of
100 mg/ml. Cells were then harvested, washed three times with PBS and filtered using sterile 70 mm cell strainers. Single cells sus-
pensions were obtained from the spleens and lymph nodes of Rag2/OT-I mice as described above. CD8+ T cells were isolated by
magnetic-activated cell separation (MACS) by negative selection using biotinylated antibodies (B220, Ter119, Gr1, CD11c,
NK1.1, F4/80, CD4, DX5) with streptavidin microbeads, andMACS columns (Miltenyi Biotec). CD8+ T cells were stained with carbox-
yfluorescein succinimidyl ester (CFSE, 5 mM), washed and 4x104 T cells were cultured with DCs at 1:1-10:1 ratio for 3 days. T cell
proliferation was assessed by CFSE dilution using flow cytometry.
In vivo cross presentation assay
DC cultures were pulsed with endotoxin-free OVA protein for 2 hr as above. Cells were pooled, harvested, washed three times with
PBS and filtered twice using sterile 70 mm cell strainers. To enrich cDC1, cells were stained with biotinylated antibodies against B220
and CD172a (FL cultures) or B220 and CD11b (FL+Notch cultures), and purified by negative selection on MACS columns. OVA-
pulsed total DCs (2.5x105 - 1x106) or OVA-pulsed enriched cDC1 (3x105) were resuspended in 0.1 mL PBS and injected i.v. into
the retroorbital sinus. Spleens were harvested or PB was collected and analyzed by flow cytometry using OVA peptide/H-2Kb
tetramer staining 7 days after DC vaccination.
Tumor challenge
B16-OVAmelanoma cells were harvested, washed twice with PBS, and filtered. A total of 2.5x105 B16-OVA cells in 0.1 mL PBSwere
injected i.v. into the retroorbital sinus 7-10 days following vaccination with OVA-pulsed DCs. Mice were monitored daily and sacri-
ficedwhenmoribund or on day 25 of observation if healthy. Lungs from perfusedmicewere harvested, fixed in 4%paraformaldehyde
for 24 hr, sectioned and stained with hematoxylin/eosin for histological examination using light microscopy. Where indicated, 4x105
B16-OVA cells in 0.2 mL PBS were injected i.v. into the tail vein.
Cell sorting and sample preparation for RNA-seq
DC populations were stained and sorted on BD FACSAria II as follows: cDC1 (CD11chi MHCII+ B220 CD24+) and cDC2 (CD11chi
MHCII+ B220 CD11b+). Sorted cells (1–3x105) were resuspended in 750 mL Trizol LS (Invitrogen), and RNA was extracted using
the Arcturus PicoPure kit (Thermo Fisher Scientific). Equal volume of 70% ethanol was added to the aqueous phase of TRIzol sam-
ples and applied to columns from the PicoPure kit. Up to 250 mL of ethanol/aqueous phasemix was loaded onto the column and spun
at 100 g for 2 min for each load. Bound RNA was washed, treated with DNase I (QIAGEN), and eluted as per manufacturer’s instruc-
tions. To remove phenol contamination, eluate was resuspended in 100 mL of Wash Buffer 1 and reloaded onto a fresh column fol-
lowed by elution. RNASeq libraries were prepared using the Clontech Ultra low RNA kit, starting with 3 ng, with 10 cycles of PCR for
cDNA amplification, and the Clontech Low Input Kit for library prep, with 7 cycles of PCR amplification, following the manufacturer’s
protocol. The amplified library was purified using AMPure beads, quantified by Qubit and QPCR, and visualized in an Agilent Bio-
analyzer. The libraries were pooled equimolarly, and run on a HiSeq 2500 as paired, 50 nucleotide in length.
RNA-Seq data processing
Sequencing reads were mapped to the mouse reference genome (GRCm38.85/mm10) using the STAR aligner (v2.5.0c) (Dobin et al.,
2013). Alignmentswere guided by aGene Transfer Format (Ensembl GTFGRCm38.85). Themean read insert sizes and their standard
deviationswere calculated using Picard tools (v.1.126) (http://broadinstitute.github.io/picard/). The read count tableswere generated
using HTSeq (v0.6.0) (Anders et al., 2015), normalized based on their library size factors using DESeq2 (v3.0) (Love et al., 2014), and
differential expression analysis was performed. The Read Per Million (RPM) normalized BigWig files were generated using BEDTools
(v2.17.0) (Quinlan and Hall, 2010) and bedGraphToBigWig tool (v4), and downstream statistical analyses and generating plots were
performed in R environment (v3.1.1) (http://www.r-project.org/).Cell Reports 23, 3658–3672.e1–e6, June 19, 2018 e5
Methods: human
Cell isolation, flow cytometry and cell sorting
Peripheral blood or bone marrow mononuclear cells (PBMC) were isolated by density centrifugation. For flow cytometry or fluores-
cence-activated cell sorting (FACS) (purity > 98%), cells were stained in aliquots of 1-3 x106 cells/50 ml of Dulbecco’s phosphate-
buffered saline with 0.1%–2% fetal calf serum and 0.4% EDTA. Dead cells, usually < 5%, were excluded by DAPI (Partec) or Zombie
(Biolegend) staining. Analysis was performed with an LSRFortessa X-20 and sorting with a FACSAria III (BD Biosciences) running BD
FACSDIVA 8.0.1 or 8.0 software, respectively. Data were processed with FlowJo 10.4.1 (Treestar, Inc). Intracellular staining was per-
formed after surface staining, lysis, and fixation (eBioscience) according to manufacturer’s instructions.
In vitro generation of dendritic cells
FACS-purified CD34+ bone marrow progenitors were cultured (typically 3000/well) in 96 well U-bottomed plates with or without pre-
seeded OP9, OP9-DL1 or OP9-DL4 stromal cells (5000/well). Culture media consisted of 200 mL a-MEM (GIBCO) supplemented with
1% penicillin/streptomycin (Sigma), 10% fetal calf serum (GIBCO), 20 ng/ml granulocyte-macrophage colony-stimulating factor
(GM-CSF, R&D systems), 100 ng/ml FLT3-ligand (FL, Immunotools), 20 ng/ml stem cell factor (SCF, Immunotools). Half the volume
of media, with cytokines, was replaced weekly. At day 14 or 21, cells were harvested on ice, passed through a 50 mm filter, washed
and stained for flow cytometric analysis or cell sorting. Cell output was normalized to 3000 input progenitors per well.
Dendritic cell functional analysis
For cytokine production, PBMC from healthy controls or in vitro-generated cells were cultured in the presence of polyinosinic:
polycytidylic acid (poly(I:C), 10 mg/ml, Invivogen), Lipopolysaccharide (LPS, 5ng/ml, Sigma), CL075 (1 mg/ml, Invivogen) and CpG
(ODN 2216, 7.5 mM, Invivogen) for 14h at 37C, 5% CO2 with addition of Brefeldin A (10 mg/ml, eBioscience) after 3 hr. Dead cells
(usually < 30%) were excluded with Zombie amine dye (Biolegend). Intracellular cytokine staining was performed after surface stain-
ing, fixation, and permeabilization (eBIoscience) according to manufacturer’s instructions.
For T cell proliferation, FACS-purified ex vivo or in vitro generated DCs (2,500-8,000 DC/well) were cultured with FACS purified
allogeneic CD3+ T cells at a ratio of 1:10 DC:T cell (n = 2-9 DC/T cell pairs). Positive controls were generated by T cell co-culture
with CD3+CD28+ beads (Dynabeads, Thermo Fisher Scientific) at T cell:bead ratio 1:1. T cell proliferation was assessed by
CFSE dilution on day 5 of culture.
NanoString nCounter Gene expression analysis
Ex vivo or culture-generated DCs were FACS purified (> 98% purity) and lysed in RLT buffer containing 1% b-mercaptoethanol, at a
concentration of 2000 cells/ml. Samples were analyzed on the NanoString nCounter FLEX platform according to manufacturer’s
instructions. Briefly, 5 ml of lysate (10,000 cells) was mixed with reporter probes, hybridization buffer, and capture probes and hybrid-
ized at 65C for 12-30 hr. Samples were then processed on the NanoString Prep station and cartridges were read on the NanoString
Digital Analyzer to yield a reporter code count (RCC) dataset. The human Immunology_V2 panel was used, supplemented with the
following 30 genes: ASIP, DAXX, MERTK, C19orf59, DBN1, Ki67, CCL17, F13A1, NDRG2, CD1c, FGD6, PACSIN1, CD207, FLT3,
PPM1N, CLEC10A, GCSAM, PRAM1, CLEC9A, GGT5, S100A12, CLNK, LPAR2, TMEM14A, COBLL1, LYVE1, UPK3A, CXCL5,
MAFF, ZBTB46.
Counts were normalized within the nSolver software (advanced analysis module version 1.1.4). The log2 transformed output data
were analyzed using R (version 3.3.3). For principal component analysis (PCA), genes expressed below 24.8 in all samples were
removed (167/608). A culture signature was derived by performing pairwise comparisons (two-tailed t test with Benjamini-Hochberg
correction of p values) of all culture versus all ex vivo populations. 102 genes with adjusted p values < 0.05 (the culture signature) were
excluded from further analysis. The remaining 339 genes were used to construct the PCA plot. Heatmaps were generated in R and
display log2 transformed expression.
QUANTIFICATION AND STATISTICAL ANALYSIS
For experimental results, all statistical calculations analysis were performed using Prism (GraphPad, La Jolla, CA). In animal exper-
iments, statistical significance of differences between experimental groups was determined by non-parametric Mann-Whitney test.
Differences in the Kaplan-Meier survival plots (Figure 5) were analyzed using log-rank test. In human cell culture experiments, sta-
tistical significance of differences between experimental groups was determined by unpaired, two-tailed Student’s t test.
For RNA-seq data, Wald test p values and adjusted p values provided by DESeq2 package were used for differential expression
analysis (adjusted p < 0.1, FC > 2) which is based on estimating dispersions and uses a negative binomial generalized linear model.
For sample clustering, we performed a classical multidimensional scaling (MDS) and a Euclidean distance based clustering. For
pathway and enrichment analysis, we used hypergeometric distribution tests performed by clusterProfiler package (adjusted
p < 0.1). The datasets were individually and comprehensively analyzed and visualized all in the R statistical environment (v3.2.5).
DATA AND SOFTWARE AVAILABILITY
The complete processed expression data from RNA-seq and Nanostring experiments are attached as Tables S1 and S5, respec-
tively. The accession number for the raw RNA-seq sequencing data reported in this paper is GEO: GSE110577.e6 Cell Reports 23, 3658–3672.e1–e6, June 19, 2018
